RC
ACET icon

RBF Capital’s Adicet Bio ACET Stock Holding History

RBF Capital’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$263K Hold
38,582
– – 0.01% 434
2025
Q4 		$325K Hold
38,582
– – 0.01% 460
2025
Q3 		$500K Hold
38,582
– – 0.02% 406
2025
Q2 		$377K Hold
38,582
– – 0.02% 459
2025
Q1 		$466K Buy
38,582
+1,011
+3% +$14.5K 0.03% 398
2024
Q4 		$578K Hold
37,571
– – 0.03% 368
2024
Q3 		$866K Buy
37,571
+14,446
+62% +$323K 0.04% 317
2024
Q2 		$448K Buy
+23,125
New +$620K 0.03% 409

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RBF Capital's ACET Position: Q1 2026 in Review

RBF Capital held its Adicet Bio (ACET) position steady in Q1 2026 at 38,582 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #434.

RBF Capital first reported a position in ACET in Q2 2024 and has held it in 8 quarters since. The position peaked at $866K in Q3 2024. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • RBF Capital held 38,582 shares of Adicet Bio worth $263K as of Q1 2026.
  • RBF Capital left its Adicet Bio share count unchanged in Q1 2026.
  • Adicet Bio made up 0.01% of RBF Capital's portfolio in Q1 2026, its #434 holding.
  • RBF Capital first reported a position in Adicet Bio in Q2 2024 and has held it in 8 quarters since.
  • RBF Capital's Adicet Bio position peaked at $866K in Q3 2024.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.